NewAmsterdam Pharma Company N.V. (NAMS) Return on equity 2022–2025
NewAmsterdam Pharma Company N.V. (NAMS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-29.7%FY2025 · since FY2022: -5.3% → -29.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -29.7% | +2.2 pp |
| FY2024 | -31.9% | +29.4 pp |
| FY2023 | -61.4% | -56.1 pp |
| FY2022 | -5.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice